Frontier IP Group PLC’s (LON:FIPP) portfolio firm, Exscientia, has begun phase 1 clinical trials of DSP-1181, the world’s first drug created by artificial intelligence (AI).
The drug, created as part of a joint development agreement with Japanese firm Sumitomo Dainippon Pharma, is designed to treat obsessive compulsive disorder (OCD).
READ: Frontier IP delighted with first funding round for The Vaccine Group
Exscientia said the project had been delivered by a “strong synergy” of research between the two companies, requiring less than 12 months to complete the exploratory research phase as opposed to the typical average of 4.5 years using conventional research techniques.
"We believe that this entry of DSP-1181, created using AI, into clinical studies is a key milestone in drug discovery”, said Exscientia chief executive Andrew Hopkins.
“We are proud that our AI drug discovery platform Centaur Chemist has contributed to generate DSP-1181 and look forward to its progression as a treatment for obsessive-compulsive disorder", he added.